Hyperion DeFi | 8-K: FY2025 Q2 Revenue Misses Estimate at USD 0

Revenue: As of FY2025 Q2, the actual value is USD 0, missing the estimate of USD 600 K.

EPS: As of FY2025 Q2, the actual value is USD -2.5.

Net Loss

• Net loss attributable to common stockholders was $8.8 million, or $2.50 per share, compared to a net loss of $11.1 million, or $16.65 per share, for the second quarter of 2024.

Research and Development Expenses

• Research and development expenses totaled $0.7 million, a decrease of $3.9 million, or 85%, compared to $4.6 million recorded for the second quarter of 2024. The decrease was driven primarily by a reduction in headcount after the termination of the Company’s CHAPERONE study in November 2024.

General and Administrative Expenses

• General and administrative expenses totaled $7.7 million, an increase of $3.9 million, or 104%, compared to $3.8 million recorded for the second quarter of 2024. The increase was due to a one-time non-cash stock-based compensation inducement grant given to a newly hired executive, as well as higher professional fees.

Cash and Cash Equivalents

• As of June 30, 2025, the Company’s unrestricted cash and cash equivalents were $7.5 million, compared to $2.1 million in unrestricted and restricted cash as of December 31, 2024.

HYPE Digital Tokens

• The Company accumulated HYPE digital tokens valued at $45.5 million as of June 30, 2025.

Outlook / Guidance

• Hyperion DeFi anticipates FDA registration of the Optejet User Filled Device (UFD) next month and expects these strategies to create powerful tailwinds for Hyperliquid’s continued growth and adoption.